I am a cancer biologist investigating mechanisms that regulate the aberrant cell proliferation in cancers, particularly melanomas. I am attempting to utilise defects in normal proliferative mechanisms as targets for novel anti-cancer therapies.
Understanding How RUVBL1 And RUVBL2 Organise Chromosomes And Their Links To Disease
Funder
National Health and Medical Research Council
Funding Amount
$605,005.00
Summary
Our proposal will provide a deep mechanistic framework to inform both clinicians in diagnosis and management of RUVBL related diseases and also therapeutically, as industry looks to use these proteins as drug targets. The great excitement of RUVBL in translation has outpaced the gathering of vital knowledge underpinning the function; knowledge this proposal will provide for the first time.
Understanding The Structure And Function Of The Chromosome Condensin Complex
Funder
National Health and Medical Research Council
Funding Amount
$620,731.00
Summary
In order to survive cells need to divide their genetic material (DNA) equally between two daughter cells. For correct cell division to occur DNA has to be correctly packaged into condensed and organised chromosomes. Improper packaging of genetic material can result in unregulated cells that may become cancerous or lead to other genetic diseases such as Down's Syndrome. Understanding the key players regulating this process is vital to allowing researchers to further work in these areas.
Investigating Deregulation Of Mitosis As A Mechanism Of Tumourigenesis In MYCN-driven Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$372,298.00
Summary
Neuroblastoma chemotherapy often only works temporarily because a small number of tumour cells can resist drugs and eventually regrow as a new tumour. These resistant cells resemble the very first cells that turn into a cancer cell at tumour initiation. We have used single cell technology to uncover genetic markers of tumour initiating cells. In this project we will determine how these marker genes cause tumour initiation and develop therapies that target them in drug resistant neuroblastoma.